Treatment of lipids and type 2 diabetes

被引：2
作者：
Hermayer K.L. [1 ]
机构：
[1] Medical University of South Carolina, Division of Endocrinology, Charleston, SC 29425-0624
来源：
Current Cardiology Reports | 2004年 / 6卷 / 6期
关键词：
Statin; Pravastatin; Fenofibrate; Ezetimibe; Absolute Risk Reduction;
D O I：
10.1007/s11886-004-0053-4
中图分类号：
学科分类号：
摘要：
The development of type 2 diabetes is increasing in epidemic proportions. There is a significant risk for cardiovascular disease, which is the most prevalent and detrimental complication for the diabetic population. Serum lipid abnormalities are common in patients with diabetes, and due to this increased vascular risk, it is recommended to aggressively treat the hyperlipidemia. Therefore, intensive lipid-lowering therapy should be used for primary and secondary prevention against macrovascular complications for patients with type 2 diabetes, in this article some of the key studies justifying the need for lipid reduction in patients with type 2 diabetes are reviewed and practical guidelines for management of the dyslipidemia are suggested. Copyright © 2004 by Current Science Inc.
引用
收藏
页码：443 / 450
页数：7
相关论文
共 51 条
[1]  
Basic Diabetes Information. Facts and Figures, The Impact of Diabetes
[2]  
Haffner S.M., Goldberg R.B., New strategies for the treatment of diabetic dyslipidemia, Diabetes Care, 25, pp. 1237-1239, (2002)
[3]  
Dyslipidemia management in adults with diabetes, Diabetes Care, 27, (2004)
[4]  
Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III): Final report, Circulation, 106, pp. 3143-3234, (2002)
[5]  
O'Brien T., Nguyen T.D., Zimmerman B.R., Hyperlipidemia and diabetes mellitus, Mayo. Clin. Proc., 73, pp. 969-976, (1998)
[6]  
Plan and operation of the Third National Health and Nutrition examination survey, 1988-1994. Series 1: Progress and collection procedures, Vital Health Statistics, 1, pp. 1-407, (1994)
[7]  
Siegal R.D., Cupples A., Schaefer E.J., Et al., Lipoproteins, apolipoproteins, and low-density lipoprotein size among diabetics in the Framingham offspring study, Metabolism, 45, pp. 1267-1272, (1996)
[8]  
Haffner S.M., Lipoprotein (a) and diabetes. An update, Diabetes Care, 16, pp. 835-840, (1993)
[9]  
Bucala R., Makita Z., Vega G., Et al., Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency, Proc. Natl. Acad. Sci. USA, 91, pp. 9441-9445, (1994)
[10]  
Henry R.R., Preventing cardiovascular complications of type 2 diabetes: Focus on lipid management, Clin. Diabetes, 19, pp. 113-120, (2001)
123456